The use of new chemotherapy drug paste stoics in the tumor cavity to treat GBM effectively

Stuart JSmith, of the Children's Brain Tumor Research Centre at the University of Nottingham School of Medicine in the UK, and others conducted an animal model study of gliomatos to assess the value of the new assembly intracavity drug delivery systemin GBM therapy, and the results were published online in Clinical Cancer Research in May 2019high-level gliomas (high-grade gliomas, HGG) are invasive and genetic heterogeneousIn recent years, the median survival of WHO IV-type glioblastoma (GBM) patients has not improved significantlyChemotherapy effects are affected by a variety of reasons, of which the blood-brain barrier (blood-brain barrier, BBB) is a very important limiting factorCurrently, the main chemotherapy drug for GBM is Temozolomide (TMZ), but it is difficult to pass through the blood-brain barrierDue to the presence of dose-dependent bone marrow suppression, TMZ dosage is difficult to increaseTMZ has a mild neurotoxicity and does not require liver metabolism, making it ideal for direct local applicationsThe in-cavity drug delivery system can be implanted in the tumor bed when the tumor is removed to the maximum safety, so that the drug penetrates the surrounding tissue, and the remaining tumor cells can obtain a higher local drug dose and minimize systemic drug responseThe Gliadel®crystals containing 3.85% carmostine (BCNU) are implants in the local release drug and have been approved by the FDA for the treatment of GBMStuart JSmith, of the Children's Brain Tumor Research Centre at the University of Nottingham School of Medicine in the UK, and others conducted an animal model study of gliomatos to assess the value of the application of new assembled intracavity drug delivery systems in GBM therapy, the results of which were published online in Clinical Cancer Research in May 2019the new drug delivery system used in the study is a biopolymer paste containing chemotherapy drugsBiopolymer paste is made from polylactic acid-hydroxyacetic copolymers (DL-lactic acid-co-glycolic acid), PLGA) and polyglycol copolymers (poly (ethylene glycol), PEG, and solidified at 37 degrees CTherefore, the paste can fit in the irregularshape of the inner wall of the tumor cavity, minimizing the spread of the drug to the normal brain essenceIn biopolymer pastes, PLGA/PEG combined with a combination of TMZ and etoposide (ETOP), while TMZ precursor drugs remained stable at low pH and functioned at higher pH hydrolysisPreviously, the animal model of the 19L cell line glioma transplant was used in the development of the 120-year-
®of Gliadel to assess the safety and efficacy of the drug, and the authors used the same animal model of gliomaresultsresults show that in LACtic acid-based PLGA/PEG paste, the Combination of TMZ and ETOP can be released into the tumor microenvironment, and the performance of TMZ precursor drugs is stableThe central lyse GBM cells are more sensitive to each chemical than the cells at the edge of the tumorBoth drugs released from PLGA/PEG paste were cytotoxic and had better effect on cell chemotherapy in the central booster region of the tumorExperiments in animals showed that after surgical removal of the in-situ 9L cell line glioma, the treatment of PLGA/PEG/TMZ/ETOP paste with radiotherapy in the tumor cavity could significantly improve the total survival of the experimental animalsHistopathologicalology confirmed the presence of tumor cells in both the tumor cavity and the outer tumor cavity of the animal, indicating that the tumor animal was in a non-progressive state of tumorconclusionsthe final authors point out that the results show that THE PLGA/PEG paste-mediated ETOP/TMZ intracavity combined radiation therapy (XRT) can significantly extend the survival of glioma animal models, indicating clinical application value.